Jupiter Endovascular Secures Series B Financing to Advance TFX Technology

What's Happening?

Jupiter Endovascular, a medical technology startup, has successfully closed an oversubscribed Series B financing round, surpassing its $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor. The funds will be used to complete the SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its Transforming Fixation (TFX) platform technology. This financing follows the FDA 510(k) clearance of the Vertex Catheter incorporating TFX and precedes the presentation of first-in-human results for the Vertex Pulmonary Embolectomy System at the Transcatheter Cardiovascular Therapeutics Conference. Jupiter Endovascular aims to address the lack of stability and control in complex cardiovascular anatomies, starting with pulmonary embolism.

Why It's Important?

The successful financing round for Jupiter Endovascular highlights the growing interest and investment in innovative medical technologies that address significant unmet needs in healthcare. The TFX platform technology promises to enhance the stability and control of catheter-based therapies, potentially transforming the treatment of complex cardiovascular conditions. This development could lead to improved patient outcomes and expand the capabilities of interventionalists in treating anatomical sites that are challenging to access with conventional methods. The support from prominent investors underscores the potential impact of Jupiter's technology on the healthcare industry, offering new possibilities for millions of patients worldwide.

What's Next?

Jupiter Endovascular is currently enrolling patients in the SPIRARE II trial, which will involve up to 145 patients across 25 sites in the U.S. and Europe. The trial aims to characterize the procedural and clinical benefits of pulmonary embolism treatment using the Vertex system with TFX technology. The company plans to expand its focus beyond pulmonary embolism to additional high-need cardiovascular applications. The presentation of SPIRARE I trial results at the upcoming TCT 2025 meeting will provide further insights into the effectiveness of the Vertex Pulmonary Embolectomy System.